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To evaluate the effectiveness and cost of low osmolarity,
nonionic contrast agents for cardiac angiography, 443
patients were randomized to receive either iopamidol or
diatrizoate. All adverse events that occurred within 24 h of
the procedure were recorded prospectively by study per-
sonnel and classified according to previously determined
criteria. Major events were defined as life threatening or
requiring a procedure to treat, or both. Costs of the
catheterization procedure, pharmacy, hospital laboratory
and treatment of adverse events were determined on the
basis of actual resource use.
A total of 20 patients (8.5%) had major and 143 (61 %)
had minor adverse events with diatrizoate use; 10 patients
Cardiac catheterization is a well established procedure to
document the presence and severity of cardiac disease.
In 1986 cardiac angiography was performed on 592.000
patients in the United States (1). Although standard contrast
agents used in angiography are relatively well tolerated.
they have a number of undesirable effects, particularly on
the cardiovascular system and kidney (2). Intracoronary
contrast injection may cause a variety of arrhythmias includ-
ing ventricular fibrillation, sinus bradycardia and atrioven-
tricular block. The negative inotropic effects of contrast
agents may induce hypotension or pulmonary edema. Renal
failure induced by contrast agents remains a major concern,
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(4.8%) had major and 53 (25%) had minor adverse events
with iopamidol (p =0.12 for major events; p < 0.0001 for
total events). Most adverse events were treated fairly easily
and inexpensively. The median overall cost was $186 higher
for patients after iopamidol use compared with diatrizoate
(p < 0.0001), but all costs except the cost of the contrast
agent were not significantly different between the two
groups. Thus, patients who received iopamidol for cardiac
angiography had a significantly lower rate of adverse events
than those who received diatrizoate, but this difference was
achieved at a considerably high overall cost.
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particularly in patients with preexisting renal insufficiency
(3,4).
Newly developed radiographic contrast agents that are
low in osmolarity appear to have a relatively low incidence
of adverse events during coronary angiography (5-8). In
small, randomized studies (9-20) intracoronary injection of
these newer agents has been associated with less bradycar-
dia and hypotension than has injection of conventional
contrast agents. However. it is not certain that the rate of
serious clinical complications such as pulmonary edema,
ventricular fibrillation and renal failure is lower with the
newer contrast media. Furthermore, the cost of low osmo-
larity contrast agents is 10 to 20 times that of conventional
agents (8) and adoption of the newer agents for routine
cardiac angiography could add more than $100 million annu-
ally to the nation's health care costs.
Adoption of new and expensive low osmolarity contrast
agents might be justified if the rate of serious adverse events
were considerably lower (7). It is possible that a reduction in
the cost of treating adverse events might offset the added
expense of the contrast agents. However, there are few data
available regarding this question. The purpose of this study
was to evaluate the relative advantages and costs of a
0735- J()97/90/$3.50
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Table 1. Classification of Adverse Events
were defined as those neither requiring major treatment nor
posing a risk to life. Data concerning any adverse events
were reviewed by a panel of at least three cardiologists
masked to treatment assignment. All adverse events were
graded as definitely related, possibly related or not related to
cardiac catheterization; adverse events were also graded as
definitely related, possibly related or not related to adminis-
tration of a contrast agent.
The research assistant also collected data regarding hos-
pital resource consumption in the 24 h after catheterization.
The number and type of laboratory tests, medications and
length of stay in the hospital and intensive care units were
recorded on standard study forms.
Patient evaluation. All patients were requested to com-
plete a self-administered questionnaire after the catheteriza-
tion procedure. They were asked, "How happy, satisfied or
pleased have you been with your care during your cardiac
catheterization test'?" The six possible responses ranged
from "Extremely happy. could not have been more satisfied
or pleased" to "Very dissatisfied, unhappy most of the
time." They were also asked, "Did you have any discomfort
from feeling hot and flushed during the test?" and "Were
you sick to your stomach during the test'?" Four possible
responses ranged from "No. none" to "Yes. severely."
Cost analysis. The cost analysis was based on the con-
cept of attributing certain resources consumed to each case,
nonionic, low osmolarity contrast agent (iopamidol) for
cardiac angiography.
Methods
Study design. The design of this study has been reported
previously (4). In brief, all patients undergoing elective
cardiac catheterization at the Veterans Affairs Medical Cen-
ter, Durham were considered eligible for the study. The
study was approved by the institutional review boards of
Duke University Medical Center and the Veterans Affairs
Medical Center, Durham.
On the basis of the initial evaluation, patients were
stratified into groups at high and low risk for adverse events
induced by contrast agents. The high risk group consisted of
patients with either diabetes mellitus (treated with insulin or
an oral hypoglycemic agent) or renal insufficiency (serum
creatinine levels 2: 133 ,umol/liter) or congestive heart failure
(rales, 53 gallop or radiographic evidence of vascular redis-
tribution or pulmonary edema); the remaining patients
formed the low risk group. Patients in the low and high risk
groups were randomized separately with use of a sealed
envelope system. The patients were masked as to the type of
contrast agent received but the laboratory staff was not. End
point data were evaluated by persons masked to treatment
assignment.
Angiographic procedure. Patients without congestive
heart failure were given intravenous fluids overnight before
angiography (usually I liter of 5% dextrose in 0.45% saline
solution) as a routine clinical precaution against nephrotox-
icity. Intravenous fluids were continued at a rate of 125 ml/h
for 4 h after the procedure. After premedication with 25 to 50
mg of diphenhydramine intravenously, catheterization was
performed with the Judkins technique. Left ventriculogra-
phy and then coronary angiography were performed with
either iopamidol (lsovue 370) or diatrizoate (Renografin-76
or Hypaque) according to randomization assignment. Ad-
ministration of heparin during the procedure was not stan-
dardized by protocol but 64% of patients randomized to
receive iopamidol and 66% of patients randomized to receive
diatrizoate were given heparin (3,000 to 5,000 U) after
arterial access was obtained. Procedural data were recorded
by the catheterization technician and cardiovascular fellow
on standardized forms for computer entry. Blood pressure
and electrocardiographic (ECG) rhythm strip were recorded
during all injections for later measurement of changes in
blood pressure and heart rate by an observer masked to the
type of contrast agent administered.
Adverse events (Table 1). A research assistant followed
up all patients for 24 h to determine the subsequent occur-
rence of adverse events, which were classified according to
a schema established before the study. Major events were
defined as those that were life threatening, required major
intervention or increased the intensity of care. Minor events
Major events
Arrhythmic
Hemodynamic
Ischemic
Allergic
Vascular
Neurologic
Renal
Miscellaneous
Minor events
Arrhythmic
Hemodynamic
Ischemic
Allergic
Vascular
Renal
Miscellaneous
Ventricular fibrillation
Sustained ventricular tachycardia
Bradycardia or atrioventricular block needing
pacing
Hypotension treated with pressors or intraaortic
balloon pump
Pulmonary edema
Acute myocardial infarction
Prolonged (?: 10 min) chest pain
Hypotension. bronchospasm or anaphylaxis
Coronary embolus or dissection. vascular injury
requiring transfusion or surgery
Stroke. transient ischemic attack
Dialysis or creatinine rise to ?:355 fLmol/liter
Aspiration or respiratory arrest
Nonsustained ventricular tachycardia
Bradycardia or atrioventricular block
responding to cough or atropine
Supraventricular tachycardia
Hypotension responsive to fluid administration
Angina (pain <10 min)
Hives
Vascular injury not requiring transfusion or
surgery
Rise in creatinine >44 fLmol/liter. peak <355
Vomiting
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*N umber of events exceeds the number of patients with events because
more than one event per patient occurred in some cases.
*N umber of events exceeds the number of patients with events because
more than one event per patient occurred in some cases.
Table 3. Adverse Events Definitely or Possibly Related to
Contrast Agent*
after injection of the contrast agent were strikingly different
between iopamidol and diatrizoate. The systolic blood pres-
sure declined to significantly lower values after diatrizoate
than after iopamidol (median 80 versus 87 mm Hg, p =
0.0007). The heart rate slowed to significantly lower levels
during injections with diatrizoate than with iopamidol (me-
dian 43 versus 55 beats/min, p = 0.0001). The longest
interval between QRS complexes was 2:3 s in 12% of
patients given diatrizoate and in none of the patients given
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14
24
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Table 2. Total Adverse Events Within 24 h of Angiography*
Major events
Ventricular fibrillation
Sustained ventricular tachycardia
Sustained bradycardia
Pulmonary Edema
Acute myocardial infarction
Prolonged angina
Coronary embolus
Coronary occlusion
Coronary dissection
Transient i,chemic attack
Respiratory arrest
Minor events
Non,ustained bradycardia
Nonsustained ventricular tachycardia
Hypotension
Angina
Hives
Hematoma
Diminished pulse
Vomiting
Nephrotoxicity
Adverse Events
Adverse Events
Major events
Ventricular fibrillation
Pulmonary edema
Prolonged angina
Coronary embolus
Minor events
Nonsustained bradycardia
Nonsustained ventricular tachycardia
Hypotension
Angina
Hives
Vomiting
Nephrotoxicity
assigning cost values to each resource and then summing the
individual costs to estimate a total cost. Costs in each
category were calculated with only the variable cost compo-
nent, that is, only the supply and personnel costs were
included and fixed costs (such as equipment) and hospital
overhead were excluded. Unit cost data were obtained from
administrative personnel at Duke University Medical Cen-
ter. Supply costs were determined directly from invoices and
personnel costs were assigned on the basis of time required
to perform a given task multiplied by the wage and fringe
benefit rate.
Catheterization costs were defined as those incurred in
the catheterization laboratory including supplies. medica-
tions and technician time. Hospital laboratory costs were
those incurred for arterial blood gas determinations. differ-
ential blood cell counts. blood chemistry panels, coagulation
studies. ECG, chest roentgenograms. urinalysis, lipid levels.
cardiac enzyme levels and other miscellaneous tests. Phar-
macy costs included medications the patient received on the
day of catheterization and the day after catheterization.
Procedure costs were those incurred because of adverse
events including the cost of treatment and any additional
hospital days needed.
Statistics. Statistical analyses of discrete valued variables
were performed with use of the chi-square or Fisher's exact
test. Continuous valued variables were analyzed with the
Wilcoxon rank sum test.
Results
Study patients. Four hundred eighty-three patients un-
derwent left heart catheterization with angiography during
the study period. Eleven patients were catheterized on an
emergency basis for acute myocardial infarction and were
not randomized, 26 patients were excluded for logistic
reasons and 3 patients refused randomization. The remaining
443 patients were randomized. 208 to receive iopamidol and
235 to receive diatrizoate. The median age of the population
was 61 years and all but three patients were men. One
hundred sixty patients were in the predefined high risk
group, 90 because of diabetes, 66 because of congestive
heart failure and 42 because of renal insufficiency (34 pa-
tients met more than one criterion for high risk).
Angiographic imaging efficacy. 10j)amidol and diatrizoate
were equivalent in imaging effectiveness. The visualization
of the coronary arteries was rated by the cardiovascular
fellows as adequate in 100% of patients given diatrizoate and
in 99% of patients given iopamidol. The quality of the
ventriculogram was adequate in 91% of patients given dia-
trizoate and in 94% of patients given iopamidol. The time
spent in the catheterization laboratory was slightly less
among patients given iopamidol than among those given
diatrizoate (median 70 versus 75 min, p = 0.34).
Adverse events (Tables 2 and 3). The immediate effects
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Table 4. Patient Subjective Evaluation According to Contrast
Agent Administered
lopamidol (%) Diatrizoate (%)
Overall satisfaction
Extremely satisfied 70 63
Very satisfied 16 17
Fairly or generally satisfied 14 17
Dissatisfied I 2
Flushing
Severe 3 10
Moderate 16 3I
Slight 43 33
None 38 26
Nausea
Severe 0 2
Moderate I 3
Mild 3 13
None % 82
iopamidol. However, the change in left ventricular end-
diastolic pressure after diatrizoate and iopamidol was com-
parable (median change 1 mm Hg in both groups. p = 0.35).
Adverse events were less frequent during the 24 h obser-
vation period after administration of iopamidol than afier
diatrizoate (Table 2). Major adverse events were noted in 20
patients (8.5%) given diatrizoate and in 10 patients (4.8%)
given iopamidol (p = 0.12), whereas minor events (unasso-
ciated with major events) were noted in 143 patients (61%)
given diatrizoate and in 53 patients (25%) given iopamidol.
The incidence of all adverse events was significantly reduced
in the iopamidol group (p < 0.0001). The vast majority of
these adverse events consisted of either transient bradycar-
dia that responded to cough or angina that responded to
sublingual nitroglycerin (Table 2).
In the case of iopamidol, fewer adverse events were
judged to be definitely or possibly related to administration
of the contrast agent (Table 3). Fourteen patients (6%) had
major and 133 (57%) had minor adverse events attributable
to diatrizoate and 4 (2%) had major and 39 (19%) had minor
adverse events attributable to iopamidol. The risk reduction
among patients given iopamidol was comparable for both
major and minor adverse events. Again. most adverse events
related to administration of the contrast agent consisted of
transient bradycardia responsive to cough or angina respon-
sive to nitroglycerin.
Patient evaluation (Table 4). The subjective evaluation by
the patient of the catheterization procedure was consider-
ably different between those who received iopamidol and
those who received diatrizoate. Overall satisfaction with the
cardiac catheterization procedure was slightly higher among
patients given iopamidol, although this was not statistically
significant. The flushing sensation associated with left ven-
triculography was blunted significantly (p < 0.001) among
Table 5. Marginal Cost (in dollars) According to Contrast
Agent Administered*
lopamidol Diatrizoate
Contrast agent 207 (207 to 207) 20 (20 to 20)
Catheterization 243 (236 to 259) 245 (237 to 262)
Laboratory 17 (0 to 36) 20 (3 to 40)
Pharmacy 22 (18 to 24) 22 (18 to 24)
Procedures o(Q to 0) 0(0 to 0)
Total 499 (479 to 540) 313 (291 to 351)
'Data are median values (25th to 75th percentiles).
patients given iopamidol. In addition, nausea associated with
the contrast injection was significantly less among patients
given iopamidol (p < O.()()]), which paralleled the difference
in contrast agent-related vomiting between patients receiv-
ing diatrizoate (6%) and iopamidol (2%) (Table 3).
Cost analysis (Table 5). Despite the marked reduction in
adverse events, the overall cost was $186 higher among
patients randomized to receive iopamidol (p < 0.0001). The
cost of treating adverse events was somewhat lower in the
patients who received iopamidol, but the amount saved was
not sufficient to offset the higher cost of the contrast agent.
The hospital length of stay after cardiac catheterization was
similar in the patients given diatrizoate and those given
iopamidol (median 2 days each). The incidence of transfer to
intensive care units was similar in both groups (6% for
diatrizoate versus 4% for iopamidol) and the length of stay in
intensive care was comparable (median 0 days, mean 0.4 in
each group).
Outcome in high risk group. Presence of diabetes, con-
gestive heart failure or renal insufficiency defined the high
risk group in this study. To determine whether this definition
was useful in separating patients into groups with different
rates of adverse events, data from all high risk patients were
combined, as were the data from all low risk patients,
regardless of randomization assignment. The 160 patients in
the predefined high risk group had an incidence of major
adverse events related to use of a contrast agent that was
twice as high as the incidence among the 283 patients in the
low risk group (6% versus 3%, p = 0.09). The median overall
cost was $70 greater in the high risk group than in the low
risk group (p = 0.0007).
Discussion
This randomized controlled trial demonstrates that ad-
verse events during and after cardiac angiography can be
reduced 50% to 70% by substitution of iopamidol for diatri-
wate. However. most adverse events were fairly minor and
could be treated easily and inexpensively. Despite the
marked reduction in adverse events, the overall median cost
(including the catheterization procedure, pharmacy, labora-
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tory tests and costs of treating adverse events) was $186
higher among patients given iopamidol, almost exclusively
because of the higher cost of the contrast agent.
Clinical effectiveness. Previous small, randomized studies
of the contrast agents iopamidol (9-12), iohexol (13-17) and
ioxaglate (18-20) during cardiac angiography have demon-
strated that these newer contrast agents reduce the incidence
of hypotension and bradycardia during contrast injection.
None of these studies has been of sufficient size to examine
the effects of these newer contrast agents on more serious
complications. A retrospective analysis of 3,313 patients
who underwent cardiac angiography at Duke University
Medical Center (21) suggested that the risk of adverse events
related to use of contrast agents could be reduced by two
thirds among patients given iopamidol in comparison with
patients given diatrizoate. That study, although it was not
randomized and had a historical control group, yielded an
estimate of risk reduction remarkably similar to that found in
the present randomized trial.
The adverse events most strikingly reduced by iopamidol
were bradycardia, angina, nausea and vomiting (Table 3).
Bradycardia during conventional contrast injection may be
due to the calcium chelating properties of the ionized mate-
rial. Most previous investigators (12,13,15,16) demonstrated
that the decrease in heart rate during injections could be
blunted by nonionic contrast material. Angina during con-
trast injection may be due to the coronary vasodilation and
reactive hyperemia induced by high osmolarity contrast
material. The relatively low osmolarity of iopamidol in
comparison with diatrizoate may be responsible for the
reduction in angina seen in this study. Vomiting during
contrast injection appears to represent a direct effect of the
contrast agent on the medullary chemoreceptor zone. Al-
though the precise mechanism for the effect is not known,
nausea and vomiting were clearly reduced in the iopamidol
group.
Although iopamidol reduced the incidence of adverse
events in this study, our results do not imply that use of the
agent would reduce the incidence of more serious events
such as renal failure, myocardial infarction, stroke or death.
In large series of patients undergoing cardiac angiography
with conventional ionic contrast agents, there has been a
reported incidence of such events of roughly 0.1%. Not
surprisingly, we did not observe any of these relatively rare
events in this study of 443 patients. More than 50,000
patients would have to be studied to deduce a difference
between event rates of 0.1% and 0.2% with good statistical
power (a ;::::80% chance of detecting a difference if one
existed) and >5,000 patients would have to be studied to
detect a difference between event rates of 1% and 2%. Thus,
only very large studies would be able to determine whether
the newer contrast agents would reduce the incidence of
these most serious complications after cardiac angiography.
The effects of iopamidol on renal function and thrombo-
embolic events appear to differ from its effect on other
adverse events. Previous data published from this study
showed similar changes in serum creatinine levels after
angiography with either iopamidol or diatrizoate (4) and
renal failure requiring dialysis has been reported among
patients given iopamidol (22). Myocardial infarction and
stroke after angiography are usually due to either mechanical
trauma or thromboembolism. Mechanical complications of
catheterization should not be affected by the type of contrast
agent used. In a previous observational study (21) from our
institution, there were five cases of coronary embolism
among 3,313 patients given iopamidol (0.15%, confidence
interval 0.05% to 0.35%) and two cases among 2,650 patients
given diatrizoate (0.09%, confidence interval 0.009% to
0.27%). Because ionic contrast agents also have greater
anticoagulant properties in vitro than nonionic agents (23),
nonionic contrast agents may actually increase the risk of
thromboembolism during cardiac catheterization. Additional
large studies will be needed to establish statistically reliable
conclusions regarding the relative effects of ionic and
nonionic contrast agents on thromboembolism.
Effects on cost. The newer contrast agents are much more
costly than conventional contrast agents. In this study the
median cost of contrast agent to the hospital was $207 per
patient for iopamidal versus $20 for diatrizoate. We found no
evidence that the higher cost of iopamidol was offset by a
reduction in the cost of treating adverse events because the
adverse events we observed were generally treated simply and
inexpensively. If these results can be extrapolated to a national
level. routine use of newer contrast agents for coronary angi-
ography would add more than $100 million in costs annually
and adoption of newer contrast agents for all angiographic
procedures could add more than $1 billion in costs annually.
Are the newer contrast agents worth the substantially
higher cost? The present study cannot answer this key
question. We observed a striking reduction in minor adverse
events but only a statistically insignificant trend toward
reduction in major events. No randomized study of the
newer contrast agents for coronary angiography has docu-
mented a reduction in death, myocardial infarction, stroke or
renal failure. As discussed earlier, we do not believe a
reduction in minor adverse events can be extrapolated to
imply that newer contrast agents would reduce the cata-
strophic complications of coronary angiography. Neverthe-
less, if it is assumed that low osmolarity contrast agents
could reduce the mortality rate for angiography from 0.1 % to
0.05%, the cost-effectiveness of routine use of iopamidol for
coronary angiography can be calculated to be $374,000 per
death prevented. Thus, even if it is assumed that the newer
contrast agents would reduce the mortality rate after coro-
nary angiography (and no solid data are yet available to
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support this hypothesis), the cost per death prevented ap-
pears to be very high.
The cost-effectiveness of low osmolarity contrast aRents
for coronary anRiography could he enhanced in one of two
ways: I) High risk patients have more to gain from use of low
osmolarity contrast agents and the greater expense in such
patients can be more easily justified. Formal cost-
effectiveness analyses of the newer contrast agents for
general angiography suggest that these agents are much
more cost-effective when applied to high risk patients (7,24).
2) The cost-effectiveness of the newer agents would be
increased substantially if the price were lowered. Despite the
introduction of several different forms of nonionic or low
osmolarity contrast agents by different manufacturers, the
price has remained quite high and price competition has yet
to emerge among these agents.
Limitations of study. This study was conducted in a
Veterans Affairs Medical Center, which does not charge
patients for services. We determined costs by counting
resources consumed and identifying only the costs that
would be expected to vary according to the number of
patients treated. For example, the cost of the catheterization
procedure included disposable supplies and personnel time
but specifically excluded hospital overhead and fixed costs
such as those for radiographic equipment. Thus. the dollar
figures represent the marginal economic cost to the hospital
of replacing diatrizoate with iopamidoI. not necessarily the
cost to patients or third party payers.
This study has a numher of limitations: I) The patients
were drawn from a Veterans Affairs Medical Center popu-
lation, which consisted almost exclusively of men and prob-
ably differed from the population in other medical centers.
2) We did not study the effect of iopamidol or diatrizoate
during coronary angioplasty and cannot comment directly on
the relative effectiveness of these agents in that setting. To
the extent that adverse events during angioplasty are due to
the contrast agent rather than to the mechanical effects of the
procedure, it would be reasonable to extrapolate our findings
to patients undergoing coronary angioplasty. 3) The cost
analysis did not determine the patient's willingness to pay
for any changes in discomfort according to the type of
contrast agent administered. 4) Finally, the potential costs
associated with low probability events or malpractice litiga-
tion could not be assessed.
Clinical implications. Routine use of iopamidol for car-
diac angiography would reduce adverse events and improve
patient comfort but add $186 to the cost for a typical patient.
We were unable to demonstrate that the higher cost of
iopamidol would be balanced by a decrease in the costs of
treating adverse events. Although additional data from larger
studies would define the efficacy of iopamidol more com-
pletely, no amount of data will eliminate the need to include
value judgments in any assessment of whether the newer.
more expensive contrast agents are worth the added cost.
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